Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: TYROBP

Summary for TYROBP

Gene information	Gene symbol	TYROBP
	Ensembl ID	ENSG00000011600
	Entrez ID	7305
	Gene name	transmembrane immune signaling adaptor TYROBP
	Synonyms	DAP12\|KARAP\|PLO-SL\|PLOSL
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: TYROBP

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	-0.582533	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.498394	2.66e-36
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	pDCs	-0.488486	1.46e-03
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.357554	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.586489	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	-0.531957	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	-0.268253	1.95e-04
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.42918	3.17e-37
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	-0.836533	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.377008	6.83e-16
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	-0.602668	4.82e-02
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	pDCs	0.569548	2.99e-02
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	cDCs	0.444946	3.59e-10
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	0.27419	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	0.940939	4.21e-22
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	pDCs	0.763355	9.16e-07
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.357629	1.77e-13
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	0.403002	7.18e-33
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	CD4+ T cells	-0.32862	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	pDCs	0.405614	1.62e-03
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	CD8+ T cells	0.661215	6.33e-24
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	NK cells	0.349427	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-0.255959	5.18e-08
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	0.346388	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	NK cells	0.324368	1.44e-29
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD8+ T cells	-0.414096	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD4+ T cells	-0.404529	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	NK cells	0.406314	9.39e-44
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	-0.263996	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	-0.374435	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	-0.347248	6.12e-16
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-0.455783	1.52e-06
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	-0.330697	2.33e-14
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	-0.282644	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Erythrocytes	1.24189	3.08e-05
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.392145	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-1.0631	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.725392	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.464679	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	Malignant cells	0.637603	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	1.07995	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Malignant cells	0.499892	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	NK cells	0.269265	2.62e-04
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD8+ T cells	-0.457377	4.51e-18
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	B cells	0.42574	6.18e-25
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	0.282584	5.28e-16

Top

Expression of TYROBP in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to TYROBP

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Gene symbol	Cell type with DEG	Interaction ID	Interacting pair	Gene A	Gene B	Integrin	Interacting cell type1	Interacting cell type2	Dataset	Timepoint	Condition
TYROBP	Malignant cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	Malignant cells	Mono/Macro	GSE111014	post	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	CD4+ T cells	GSE111014	post	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	CD8+ T cells	GSE111014	post	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	Mono/Macro	GSE111014	post	resistant
TYROBP	Malignant cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	CD4+ T cells	Malignant cells	GSE111014	post	sensitive
TYROBP	Malignant cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	Mono/Macro	Malignant cells	GSE111014	post	sensitive
TYROBP	Malignant cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	Malignant cells	GSE111014	post	sensitive
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	CD4+ T cells	GSE111014	post	sensitive
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	CD8+ T cells	GSE111014	post	sensitive
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	Malignant cells	GSE111014	post	sensitive
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	Mono/Macro	GSE111014	post	sensitive
TYROBP	Malignant cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	Malignant cells	Malignant cells	GSE111014	pre	resistant
TYROBP	Malignant cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	Malignant cells	Mono/Macro	GSE111014	pre	resistant
TYROBP	Malignant cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	Mono/Macro	Malignant cells	GSE111014	pre	resistant
TYROBP	Malignant cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	Malignant cells	GSE111014	pre	resistant
TYROBP	Malignant cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	Malignant cells	Mono/Macro	GSE111014	pre	sensitive
TYROBP	Malignant cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	Mono/Macro	Malignant cells	GSE111014	pre	sensitive
TYROBP	Malignant cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	Malignant cells	GSE111014	pre	sensitive
TYROBP	CD8+ T cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	Mono/Macro	CD8+ T cells	GSE161801_IMiD	post	resistant
TYROBP	CD8+ T cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	CD8+ T cells	GSE161801_IMiD	post	resistant
TYROBP	CD8+ T cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	cDCs	CD8+ T cells	GSE161801_IMiD	post	resistant
TYROBP	CD8+ T cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	pDCs	CD8+ T cells	GSE161801_IMiD	post	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	Mono/Macro	NK cells	GSE161801_IMiD	post	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	B cells	GSE161801_IMiD	post	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	CD4+ T cells	GSE161801_IMiD	post	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	CD8+ T cells	GSE161801_IMiD	post	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	Malignant cells	GSE161801_IMiD	post	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	Mono/Macro	GSE161801_IMiD	post	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	NK cells	GSE161801_IMiD	post	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	Progenitors	GSE161801_IMiD	post	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	cDCs	GSE161801_IMiD	post	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	pDCs	GSE161801_IMiD	post	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	cDCs	NK cells	GSE161801_IMiD	post	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	pDCs	NK cells	GSE161801_IMiD	post	resistant
TYROBP	B cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	Mono/Macro	B cells	GSE161801_IMiD	pre	resistant
TYROBP	B cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	B cells	GSE161801_IMiD	pre	resistant
TYROBP	B cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	cDCs	B cells	GSE161801_IMiD	pre	resistant
TYROBP	B cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	pDCs	B cells	GSE161801_IMiD	pre	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	Mono/Macro	NK cells	GSE161801_IMiD	pre	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	B cells	GSE161801_IMiD	pre	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	CD4+ T cells	GSE161801_IMiD	pre	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	CD8+ T cells	GSE161801_IMiD	pre	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	Malignant cells	GSE161801_IMiD	pre	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	Mono/Macro	GSE161801_IMiD	pre	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	NK cells	GSE161801_IMiD	pre	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	Progenitors	GSE161801_IMiD	pre	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	cDCs	GSE161801_IMiD	pre	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	NK cells	pDCs	GSE161801_IMiD	pre	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	cDCs	NK cells	GSE161801_IMiD	pre	resistant
TYROBP	NK cells	CPI-SS014C07723	TYROBP_CD44	TYROBP	CD44	False	pDCs	NK cells	GSE161801_IMiD	pre	resistant

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating TYROBP

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
TYROBP	hsa-miR-218-5p	84.5156	NM_198125

Page: 1

Top

Motifs and transcription factors (TFs) regulating TYROBP

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
TYROBP	taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr	CREB1 (directAnnotation).
TYROBP	kznf__ZSCAN29_TF_Evolution_PBM	ZSCAN29 (directAnnotation).
TYROBP	metacluster_27.20	ZNF708; ZNF787; ZNF787; ZNF85 (directAnnotation).
TYROBP	kznf__ZNF18_Imbeault2017_OM_RCADE	ZNF18 (directAnnotation).
TYROBP	metacluster_31.3	ZSCAN20; ZSCAN29 (directAnnotation).
TYROBP	metacluster_71.5	HIF1A (directAnnotation).
TYROBP	kznf__ZNF418_Imbeault2017_RP_ChIP-seq	ZNF418 (directAnnotation).
TYROBP	tfdimers__MD00076	HNF1A; HNF1B; PPARG (directAnnotation).
TYROBP	taipale_tf_pairs__TEAD4_SPIB_RGAATGCGGAAGTN_CAP_1	SPIB; TEAD4 (directAnnotation).
TYROBP	kznf__ZNF77_Imbeault2017_OM_MEME	ZNF77 (directAnnotation).
TYROBP	transfac_pro__M05768	ZNF544 (directAnnotation).
TYROBP	taipale_tf_pairs__HOXD12_ETV4_RSCGGAAGTCGTAAAN_CAP	ETV4; HOXD12 (directAnnotation).
TYROBP	metacluster_172.16	ZNF48 (directAnnotation). ZNF48 (inferredBy_Orthology).
TYROBP	metacluster_85.1	FOXH1; ZNF8; ZNF8 (directAnnotation).
TYROBP	metacluster_168.4	ZNF652 (directAnnotation).
TYROBP	taipale_tf_pairs__GCM2_SOX15_RTRCGGGNNNNRNACAAWN_CAP	GCM2; SOX15 (directAnnotation).
TYROBP	transfac_pro__M06913	ZNF256 (directAnnotation).
TYROBP	metacluster_196.2	MECOM; NR2C1; NR2C1; PPARD; PPARD; PRDM16; RARA; RARA; RARB; RARB; RARG; RARG; RORB; RORB; RORC; RORC; RUNX1; RXRA; RXRA; RXRB; RXRB; RXRG; RXRG; RXRG; RXRG; THRB; THRB (directAnnotation). RXRA (inferredBy_Orthology).
TYROBP	tfdimers__MD00545	ETS1; SOX10 (directAnnotation).
TYROBP	tfdimers__MD00030	NR3C1 (directAnnotation).
TYROBP	transfac_pro__M06150	ZNF81 (directAnnotation).
TYROBP	metacluster_90.5	NR5A2; NR5A2 (directAnnotation). ESRRB; NR5A1; NR5A1; NR5A1; NR5A2; NR5A2; NR5A2 (inferredBy_Orthology).
TYROBP	metacluster_71.2	EPAS1 (directAnnotation).
TYROBP	transfac_pro__M01249	EPAS1 (directAnnotation).
TYROBP	homer__GCACGTACCC_HIF2a	EPAS1 (directAnnotation).
TYROBP	transfac_pro__M06688	ZKSCAN7 (directAnnotation).
TYROBP	transfac_pro__M06881	ZNF549 (directAnnotation).
TYROBP	metacluster_57.5	ZKSCAN5 (directAnnotation).
TYROBP	kznf__ZNF454_Imbeault2017_RP_RCADE	ZNF454 (directAnnotation).
TYROBP	metacluster_78.17	PAX3 (directAnnotation).
TYROBP	metacluster_78.19	PAX7 (directAnnotation).
TYROBP	metacluster_21.5	HOXB2; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF2; HSF2; HSF2; HSF2; HSF2; HSF2; HSF4; HSF4; HSF4 (directAnnotation). HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF2; HSF2; HSF2; HSF2; HSF4; HSF4; HSF4; HSF4; HSF5; HSF5; HSF5; HSF5; HSFX1; HSFX1; HSFX1; HSFX1; HSFX2; HSFX2; HSFX2; HSFX2; HSFX3; HSFX3; HSFX3; HSFX3; HSFX4; HSFX4; HSFX4; HSFX4; HSFY1; HSFY1; HSFY1; HSFY1; HSFY2; HSFY2; HSFY2; HSFY2 (inferredBy_Orthology).
TYROBP	metacluster_89.2	ZNF329 (directAnnotation).
TYROBP	metacluster_78.18	PAX7 (directAnnotation).
TYROBP	metacluster_78.20	PAX7 (inferredBy_Orthology).
TYROBP	metacluster_172.8	SIX1 (directAnnotation).
TYROBP	cisbp__M00237	GFI1 (directAnnotation).
TYROBP	tfdimers__MD00012	ETS1; YY1 (directAnnotation).
TYROBP	hocomoco__HSF1_MOUSE.H11MO.1.A	HSF1 (inferredBy_Orthology).
TYROBP	transfac_pro__M05972	ZNF701 (directAnnotation).
TYROBP	taipale_tf_pairs__TEAD4_SPIB_RGAATGCGGAAGTN_CAP_2	SPIB; TEAD4 (directAnnotation).
TYROBP	tfdimers__MD00351	IRF8; RFX1; RFX2; RFX3; RFX4; RFX5; RFXANK; RFXAP (directAnnotation).
TYROBP	metacluster_79.9	DPF1; DPF1; ZBTB45; ZBTB45 (directAnnotation).
TYROBP	taipale_tf_pairs__TEAD4_TBX21_ANGTGTGAATWCY_CAP_repr	TBX21; TEAD4 (directAnnotation).
TYROBP	transfac_pro__M06339	ZNF425 (directAnnotation).
TYROBP	metacluster_52.4	ZNF276; ZNF276 (directAnnotation). ZSCAN21 (inferredBy_Orthology).
TYROBP	hocomoco__ZN502_HUMAN.H11MO.0.C	ZNF502 (directAnnotation).
TYROBP	tfdimers__MD00600	MEIS1; NR1H4; RXRA (directAnnotation).
TYROBP	transfac_pro__M05750	ZNF77 (directAnnotation).
TYROBP	taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT	ELF2 (directAnnotation).

Page: 1 2

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."